Novel combined vaccine composition preferentially for administration to adolescents
are provided, comprising a hepatitis B viral antigen and a herpes simplex viral
antigen and optionally in addition one or more of the following: an EBV antigen,
a hepatitis A antigen or inactivated attenuated virus, an HPV antigen, a V2V antigen,
a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are
formulated with an adjuvant which is a preferential stimulator of TH1 cell response
such as 3D-MPL and QS21.